Do analysts rate CYPH or KZIA?

Novogen has a consensus price target of $23.75, indicating a potential upside of 66.32%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Cypherpunk Technologies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cypherpunk Technologies 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has higher valuation & earnings, CYPH or KZIA?

Cypherpunk Technologies has higher earnings, but lower revenue than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cypherpunk Technologies N/A N/A $4.82M -$0.02 N/A Novogen $30K 785.40 -$13.41M N/A N/A

Is CYPH or KZIA more profitable?

Novogen's return on equity of 0.00% beat Cypherpunk Technologies' return on equity. Company Net Margins Return on Equity Return on Assets Cypherpunk Technologies N/A -48.33% -42.21% Novogen N/A N/A N/A

Which has stronger valuation and earnings, CTOR or KZIA?

Novogen has higher revenue and earnings than Citius Oncology. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Citius Oncology N/A N/A -$24.76M -$0.47 N/A Novogen $30K 785.40 -$13.41M N/A N/A

Is CTOR or KZIA more profitable?

Novogen's return on equity of 0.00% beat Citius Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Citius Oncology N/A -99.47% -42.16% Novogen N/A N/A N/A

Which has preferable valuation and earnings, KZIA or HYFT?

Novogen has higher earnings, but lower revenue than MindWalk. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 785.40 -$13.41M N/A N/A MindWalk $17.59M 4.09 -$21.69M -$0.20 N/A

Is KZIA or HYFT more profitable?

Novogen has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Novogen's return on equity of 0.00% beat MindWalk's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A MindWalk -66.79% -69.37% -39.74%

Does the media favor KZIA or HYFT?

In the previous week, MindWalk had 3 more articles in the media than Novogen. MarketBeat recorded 6 mentions for MindWalk and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat MindWalk's score of 0.61 indicating that Novogen is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive MindWalk 1 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate EXOZ or KZIA?

Novogen has a consensus target price of $23.75, indicating a potential upside of 66.32%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than eXoZymes. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score eXoZymes 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60

Which has higher earnings & valuation, EXOZ or KZIA?

eXoZymes has higher revenue and earnings than Novogen. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio eXoZymes $70K 860.11 -$9.16M -$1.14 N/A Novogen $30K 785.40 -$13.41M N/A N/A

Is EXOZ or KZIA more profitable?

Novogen's return on equity of 0.00% beat eXoZymes' return on equity. Company Net Margins Return on Equity Return on Assets eXoZymes N/A -220.63% -141.26% Novogen N/A N/A N/A

Does the media refer more to EXOZ or KZIA?

In the previous week, Novogen had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Novogen and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Novogen's score of 0.96 indicating that eXoZymes is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment eXoZymes 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate KZIA or XBIT?

Novogen currently has a consensus target price of $23.75, indicating a potential upside of 66.32%. Given Novogen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Novogen is more favorable than XBiotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Novogen 1 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.60 XBiotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better valuation and earnings, KZIA or XBIT?

Novogen has higher revenue and earnings than XBiotech. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Novogen $30K 785.40 -$13.41M N/A N/A XBiotech N/A N/A -$45.54M -$1.32 N/A

Is KZIA or XBIT more profitable?

Novogen's return on equity of 0.00% beat XBiotech's return on equity. Company Net Margins Return on Equity Return on Assets Novogen N/A N/A N/A XBiotech N/A -26.10% -25.06%

Does the media favor KZIA or XBIT?

In the previous week, Novogen and Novogen both had 3 articles in the media. XBiotech's average media sentiment score of 1.31 beat Novogen's score of 0.96 indicating that XBiotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Novogen 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive XBiotech 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Novogen (KZIA) Competitors

$14.28 0.00 (0.00%)

Closing price 06/12/2026 04:00 PM Eastern

Extended Trading

$14.86 +0.58 (+4.08%)

As of 09:25 AM Eastern

Compare

KZIA vs. CYPH, CTOR, HYFT, EXOZ, and XBIT

Should you buy Novogen stock or one of its competitors? MarketBeat compares Novogen with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Novogen include Cypherpunk Technologies (CYPH), Citius Oncology (CTOR), MindWalk (HYFT), eXoZymes (EXOZ), and XBiotech (XBIT). These companies are all part of the "pharmaceutical products" industry.

How does Novogen compare to Cypherpunk Technologies?

Cypherpunk Technologies (NASDAQ:CYPH) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, media sentiment, earnings, dividends, risk, institutional ownership, profitability and valuation.

Cypherpunk Technologies has a beta of -0.02, indicating that its stock price is 102% less volatile than the broader market. Comparatively, Novogen has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

30.5% of Cypherpunk Technologies shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 3.5% of Cypherpunk Technologies shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Cypherpunk Technologies has higher earnings, but lower revenue than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cypherpunk Technologies	N/A	N/A	$4.82M	-$0.02	N/A
Novogen	$30K	785.40	-$13.41M	N/A	N/A

Novogen has a consensus price target of $23.75, indicating a potential upside of 66.32%. Given Novogen's stronger consensus rating and higher probable upside, analysts plainly believe Novogen is more favorable than Cypherpunk Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cypherpunk Technologies	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Novogen's return on equity of 0.00% beat Cypherpunk Technologies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cypherpunk Technologies	N/A	-48.33%	-42.21%
Novogen	N/A	N/A	N/A

In the previous week, Novogen had 2 more articles in the media than Cypherpunk Technologies. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Cypherpunk Technologies. Cypherpunk Technologies' average media sentiment score of 1.89 beat Novogen's score of 0.96 indicating that Cypherpunk Technologies is being referred to more favorably in the media.

Company	Overall Sentiment
Cypherpunk Technologies	Very Positive
Novogen	Positive

Summary

Novogen beats Cypherpunk Technologies on 9 of the 12 factors compared between the two stocks.

How does Novogen compare to Citius Oncology?

Citius Oncology (NASDAQ:CTOR) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, analyst recommendations, risk, profitability, dividends, media sentiment and valuation.

Novogen's return on equity of 0.00% beat Citius Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Citius Oncology	N/A	-99.47%	-42.16%
Novogen	N/A	N/A	N/A

In the previous week, Novogen had 2 more articles in the media than Citius Oncology. MarketBeat recorded 3 mentions for Novogen and 1 mentions for Citius Oncology. Citius Oncology's average media sentiment score of 1.89 beat Novogen's score of 0.96 indicating that Citius Oncology is being referred to more favorably in the media.

Company	Overall Sentiment
Citius Oncology	Very Positive
Novogen	Positive

Citius Oncology has a beta of 3.42, meaning that its share price is 242% more volatile than the broader market. Comparatively, Novogen has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market.

70.5% of Citius Oncology shares are owned by institutional investors. Comparatively, 30.9% of Novogen shares are owned by institutional investors. 9.8% of Citius Oncology shares are owned by company insiders. Comparatively, 1.0% of Novogen shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Novogen has higher revenue and earnings than Citius Oncology.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Citius Oncology	N/A	N/A	-$24.76M	-$0.47	N/A
Novogen	$30K	785.40	-$13.41M	N/A	N/A

Citius Oncology presently has a consensus price target of $6.00, indicating a potential upside of 803.61%. Novogen has a consensus price target of $23.75, indicating a potential upside of 66.32%. Given Citius Oncology's higher possible upside, research analysts plainly believe Citius Oncology is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Citius Oncology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Novogen beats Citius Oncology on 7 of the 12 factors compared between the two stocks.

How does Novogen compare to MindWalk?

Novogen (NASDAQ:KZIA) and MindWalk (NASDAQ:HYFT) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, profitability, earnings, institutional ownership, media sentiment, valuation and risk.

In the previous week, MindWalk had 3 more articles in the media than Novogen. MarketBeat recorded 6 mentions for MindWalk and 3 mentions for Novogen. Novogen's average media sentiment score of 0.96 beat MindWalk's score of 0.61 indicating that Novogen is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
MindWalk	1 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen has a net margin of 0.00% compared to MindWalk's net margin of -66.79%. Novogen's return on equity of 0.00% beat MindWalk's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
MindWalk	-66.79%	-69.37%	-39.74%

30.9% of Novogen shares are held by institutional investors. Comparatively, 6.7% of MindWalk shares are held by institutional investors. 1.0% of Novogen shares are held by insiders. Comparatively, 6.8% of MindWalk shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Novogen presently has a consensus target price of $23.75, indicating a potential upside of 66.32%. MindWalk has a consensus target price of $5.00, indicating a potential upside of 220.51%. Given MindWalk's higher probable upside, analysts plainly believe MindWalk is more favorable than Novogen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
MindWalk	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

Novogen has higher earnings, but lower revenue than MindWalk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	785.40	-$13.41M	N/A	N/A
MindWalk	$17.59M	4.09	-$21.69M	-$0.20	N/A

Novogen has a beta of 2.17, suggesting that its share price is 117% more volatile than the broader market. Comparatively, MindWalk has a beta of 0.79, suggesting that its share price is 21% less volatile than the broader market.

Summary

Novogen beats MindWalk on 9 of the 14 factors compared between the two stocks.

How does Novogen compare to eXoZymes?

eXoZymes (NASDAQ:EXOZ) and Novogen (NASDAQ:KZIA) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, valuation, profitability, risk, earnings, dividends and media sentiment.

30.9% of Novogen shares are owned by institutional investors. 72.4% of eXoZymes shares are owned by insiders. Comparatively, 1.0% of Novogen shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

eXoZymes has higher revenue and earnings than Novogen.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
eXoZymes	$70K	860.11	-$9.16M	-$1.14	N/A
Novogen	$30K	785.40	-$13.41M	N/A	N/A

Novogen has a consensus target price of $23.75, indicating a potential upside of 66.32%. Given Novogen's stronger consensus rating and higher possible upside, analysts plainly believe Novogen is more favorable than eXoZymes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
eXoZymes	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

In the previous week, Novogen had 1 more articles in the media than eXoZymes. MarketBeat recorded 3 mentions for Novogen and 2 mentions for eXoZymes. eXoZymes' average media sentiment score of 0.98 beat Novogen's score of 0.96 indicating that eXoZymes is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
eXoZymes	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen's return on equity of 0.00% beat eXoZymes' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
eXoZymes	N/A	-220.63%	-141.26%
Novogen	N/A	N/A	N/A

eXoZymes has a beta of 2.66, indicating that its stock price is 166% more volatile than the broader market. Comparatively, Novogen has a beta of 2.17, indicating that its stock price is 117% more volatile than the broader market.

Summary

Novogen beats eXoZymes on 7 of the 13 factors compared between the two stocks.

How does Novogen compare to XBiotech?

Novogen (NASDAQ:KZIA) and XBiotech (NASDAQ:XBIT) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their risk, media sentiment, profitability, institutional ownership, dividends, earnings, analyst recommendations and valuation.

30.9% of Novogen shares are owned by institutional investors. Comparatively, 55.7% of XBiotech shares are owned by institutional investors. 1.0% of Novogen shares are owned by insiders. Comparatively, 30.8% of XBiotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Novogen has higher revenue and earnings than XBiotech.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Novogen	$30K	785.40	-$13.41M	N/A	N/A
XBiotech	N/A	N/A	-$45.54M	-$1.32	N/A

Novogen currently has a consensus target price of $23.75, indicating a potential upside of 66.32%. Given Novogen's stronger consensus rating and higher possible upside, equities research analysts clearly believe Novogen is more favorable than XBiotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Novogen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60
XBiotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, Novogen and Novogen both had 3 articles in the media. XBiotech's average media sentiment score of 1.31 beat Novogen's score of 0.96 indicating that XBiotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Novogen	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
XBiotech	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Novogen's return on equity of 0.00% beat XBiotech's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Novogen	N/A	N/A	N/A
XBiotech	N/A	-26.10%	-25.06%

Novogen has a beta of 2.17, meaning that its share price is 117% more volatile than the broader market. Comparatively, XBiotech has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

Summary

Novogen beats XBiotech on 8 of the 11 factors compared between the two stocks.

Get Novogen News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KZIA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KZIA vs. The Competition

Export

Metric	Novogen	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$23.56M	$3.39B	$6.52B	$12.05B
Dividend Yield	N/A	2.25%	2.67%	5.66%
P/E Ratio	N/A	20.00	24.00	24.42
Price / Sales	785.40	303.75	533.77	123.88
Price / Cash	N/A	53.61	27.48	37.92
Price / Book	-2.67	8.32	10.55	6.82
Net Income	-$13.41M	$23.94M	$3.57B	$337.56M
7 Day Performance	25.26%	1.84%	0.59%	1.16%
1 Month Performance	8.51%	-0.04%	1.55%	3.16%
1 Year Performance	53.55%	44.82%	25.41%	30.60%

Novogen Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KZIA Novogen	2.2224 of 5 stars	$14.28 flat	$23.75 +66.3%	+53.5%	$23.56M	$30K	N/A	12	Gap Down
CYPH Cypherpunk Technologies	0.5921 of 5 stars	$0.68 -4.6%	N/A	+58.6%	$75.40M	N/A	N/A	40	Positive News Gap Up
CTOR Citius Oncology	1.9857 of 5 stars	$0.72 -10.0%	$6.00 +733.6%	-54.8%	$74.38M	N/A	N/A	N/A	Positive News
HYFT MindWalk	3.0651 of 5 stars	$1.66 +3.8%	$5.00 +201.2%	N/A	$73.85M	$17.59M	N/A	80
EXOZ eXoZymes	0.6135 of 5 stars	$7.80 -9.5%	N/A	-44.6%	$73.09M	$70K	N/A	29	Gap Up High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KZIA) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Novogen (KZIA) Competitors

KZIA vs. CYPH, CTOR, HYFT, EXOZ, and XBIT

How does Novogen compare to Cypherpunk Technologies?

Summary

How does Novogen compare to Citius Oncology?

Summary

How does Novogen compare to MindWalk?

Summary

How does Novogen compare to eXoZymes?

Summary

How does Novogen compare to XBiotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Novogen (KZIA) Competitors

KZIA vs. CYPH, CTOR, HYFT, EXOZ, and XBIT

How does Novogen compare to Cypherpunk Technologies?

Which has more risk & volatility, CYPH or KZIA?

Do insiders & institutionals believe in CYPH or KZIA?

Which has higher valuation & earnings, CYPH or KZIA?

Do analysts rate CYPH or KZIA?

Is CYPH or KZIA more profitable?

Does the media prefer CYPH or KZIA?

Summary

How does Novogen compare to Citius Oncology?

Is CTOR or KZIA more profitable?

Does the media refer more to CTOR or KZIA?

Which has more volatility & risk, CTOR or KZIA?

Do insiders and institutionals have more ownership in CTOR or KZIA?

Which has stronger valuation and earnings, CTOR or KZIA?

Do analysts recommend CTOR or KZIA?

Summary

How does Novogen compare to MindWalk?

Does the media favor KZIA or HYFT?

Is KZIA or HYFT more profitable?

Do insiders & institutionals believe in KZIA or HYFT?

Do analysts recommend KZIA or HYFT?

Which has preferable valuation and earnings, KZIA or HYFT?

Which has more volatility and risk, KZIA or HYFT?

Summary

How does Novogen compare to eXoZymes?

Do institutionals & insiders have more ownership in EXOZ or KZIA?

Which has higher earnings & valuation, EXOZ or KZIA?

Do analysts rate EXOZ or KZIA?

Does the media refer more to EXOZ or KZIA?

Is EXOZ or KZIA more profitable?

Which has more volatility and risk, EXOZ or KZIA?

Summary

How does Novogen compare to XBiotech?

Do institutionals & insiders believe in KZIA or XBIT?

Which has better valuation and earnings, KZIA or XBIT?

Do analysts rate KZIA or XBIT?

Does the media favor KZIA or XBIT?

Is KZIA or XBIT more profitable?

Which has more risk & volatility, KZIA or XBIT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KZIA vs. The Competition

Novogen Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools